Patents Examined by R. Clarke
-
Patent number: 10793848Abstract: The invention relates to an immobilized protein material comprising a protein that is immobilized on a glass material or organic polymer through affinity tag binding. The glass material may be a porous glass material such as (hybrid) controlled porosity glass. The invention also relates to the use of an immobilized enzyme material as a heterogeneous biocatalyst in chemical synthesis. The invention further relates to a method for the immobilization of affinity tagged proteins on a glass material or organic polymer, and to a method for the purification and isolation of affinity tagged proteins by the immobilization of such proteins on a glass material or organic polymer.Type: GrantFiled: January 30, 2015Date of Patent: October 6, 2020Assignee: ENGINZYME ABInventors: Karim Engelmark Cassimjee, Jan-Erling Bäckvall
-
Patent number: 10758596Abstract: Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings.Type: GrantFiled: August 21, 2019Date of Patent: September 1, 2020Assignee: ZIOLASE, LLCInventors: Svetlana A. Ivanova, Dennis W. Davis, Brad W. Arenz, Thomas K. Connellan
-
Patent number: 10711242Abstract: According to one aspect and example, a method for facilitating cellular interactions in biological tissue provides controllable activation of a selected type of stem cell among a plurality of cell types present in the tissue. The method includes various steps including the introduction of a microbial opsin into a region of the tissue that includes a selected type of stem cell, by expressing the microbial opsin in the stem cell. A light source is then introduced near the stem cell, and the light source is used to controllably activate the light source to direct pulses of illumination from the light source to the selected type of stem cell, for selectively controlling the growth and development of the stem cell in a manner that is independent of the growth and development of the other types of cells.Type: GrantFiled: June 17, 2009Date of Patent: July 14, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Deisseroth, Albrecht Stroh, M. Bret Schneider, Raag D. Airan
-
Patent number: 10682310Abstract: Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof.Type: GrantFiled: March 17, 2016Date of Patent: June 16, 2020Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Ronald A. Siegel, Mamta Kapoor, Narsihmulu Cheryala, Gunda I. Georg, James C. Cloyd
-
Patent number: 10612076Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: GrantFiled: April 10, 2017Date of Patent: April 7, 2020Assignees: The Children's Medical Center Corporation, The U.S.A., As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 10596207Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: GrantFiled: January 5, 2017Date of Patent: March 24, 2020Assignee: INTREXON ACTOBIOTICS NVInventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
-
Patent number: 10575515Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.Type: GrantFiled: May 4, 2011Date of Patent: March 3, 2020Assignee: The General Hospital CorporationInventors: Martin L. Yarmush, Mehmet Toner, Maria-Louisa Izamis, Timothy Antonie Berendsen, Robert Marius Bieganski, Osman Berk Usta, Basak Elif Uygun, Mustafa Korkut Uygun, Sinem Perk
-
Patent number: 10561691Abstract: The present invention provides a novel lactic acid bacterium having antioxidant and anti-aging functions and a dementia alleviation effect, and more specifically, provides Lactobacillus pentosus var. plantarum C29 KCCM11291P and Lactobacillus curvatus C3 KCCM430009. In addition, the present invention provides an antioxidant and anti-aging pharmaceutical composition and a dietary supplement containing the Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 of the present invention as an active ingredient, and a composition for preventing or treating dementia and a dietary supplement for preventing or alleviating dementia, containing Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 as an active ingredient. Additionally, the present invention provides a composition for preventing or treating dementia, containg a fermentation composition, as an active ingredient, fermented by Lactobacullus pentosus var.Type: GrantFiled: July 5, 2017Date of Patent: February 18, 2020Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITYInventors: Dong-Hyun Kim, Myung Joo Han, Il-Hoon Jung, Myung-Ah Jung
-
Patent number: 10563169Abstract: The present invention relates to dry cell culture media comprising amino acid components of certain particle size. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using amino acid components of certain particle sizes significantly reduces that problem.Type: GrantFiled: November 13, 2015Date of Patent: February 18, 2020Assignee: Merck Patent GmbHInventor: Joerg Von Hagen
-
Patent number: 10465160Abstract: An object of the present invention is to develop a means capable of maintaining the enzymatic activity of a microorganism even in a dry state. Provided is a method for producing a dry microbial cell powder maintaining an enzyme titer, characterized by comprising adding a carbohydrate to a liquid of microbial cells having an enzymatic activity and then drying the liquid. Also provided is a dry microbial cell powder obtained by the method.Type: GrantFiled: April 12, 2012Date of Patent: November 5, 2019Assignee: Kabushiki Kaisha Yakult HonshaInventors: Masakazu Ikeda, Hiroshi Ishikawa, Kisaku Shimura, Yuki Fukuda, Masahiko Ito
-
Patent number: 10465234Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: GrantFiled: October 24, 2018Date of Patent: November 5, 2019Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 10421663Abstract: According to the present invention, organic material is converted to biogas through anaerobic digestion and the biogas is purified to yield a combustible fluid feedstock comprising methane. A fuel production facility utilizes or arranges to utilize combustible fluid feedstock to generate renewable hydrogen that is used to hydrogenate crude oil derived hydrocarbons in a process to make transportation or heating fuel. The renewable hydrogen is combined with crude oil derived hydrocarbons that have been desulfurized under conditions to hydrogenate the liquid hydrocarbon with the renewable hydrogen or alternatively, the renewable hydrogen can be added to a reactor operated so as to simultaneously desulfurize and hydrogenate the hydrocarbons. The present invention enables a party to receive a renewable fuel credit for the transportation or heating fuel.Type: GrantFiled: November 29, 2018Date of Patent: September 24, 2019Assignee: Iogen CorporationInventor: Brian Foody
-
Patent number: 10420822Abstract: Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings.Type: GrantFiled: June 26, 2017Date of Patent: September 24, 2019Assignee: ZIOLASE, LLCInventors: Svetlana A. Ivanova, Dennis W. Davis, Brad W. Arenz, Thomas K. Connellan
-
Patent number: 10352925Abstract: The invention relates generally to compositions and methods for the detection of zinc. In particular, compositions and methods are provided to detect changes in cellular zinc concentration and to correlate them to cellular phenomena.Type: GrantFiled: October 1, 2014Date of Patent: July 16, 2019Assignee: Northwestern UniversityInventors: Teresa K. Woodruff, Thomas V. O'Halloran, Alison M. Kim, Emily Que, Betty Kong, Miranda Bernhardt
-
Patent number: 10323269Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: GrantFiled: February 23, 2017Date of Patent: June 18, 2019Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 10272118Abstract: The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries.Type: GrantFiled: February 12, 2014Date of Patent: April 30, 2019Assignee: RepliCel Life Sciences Inc.Inventors: Rolf Hoffmann, Kevin John McElwee
-
Patent number: 10265410Abstract: Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.Type: GrantFiled: April 15, 2016Date of Patent: April 23, 2019Assignee: Halozyme, Inc.Inventors: Harold Michael Shepard, Curtis Thompson, Xiaoming Li, Gregory I. Frost
-
Patent number: 10240124Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: GrantFiled: September 19, 2012Date of Patent: March 26, 2019Assignee: BioLamina ABInventors: Karl Tryggvason, Sergey Rodin
-
Patent number: 10238118Abstract: The disclosure describes fungal organisms and preparations useful for inhibiting infection by Xylella sp. and in the treatment of Pierce's Disease.Type: GrantFiled: September 2, 2016Date of Patent: March 26, 2019Assignee: The Regents of the University of CaliforniaInventors: Philippe Rolshausen, Mary Caroline Roper, Katherine Maloney, Thomas Aldrich
-
Patent number: 10188769Abstract: Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.Type: GrantFiled: June 25, 2014Date of Patent: January 29, 2019Assignees: UNIVERSITY OF SOUTHERN CALIFORNIA, CALIFORNIA INSTITUTE OF TECHNOLOGY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Mark S. Humayun, Ashish Ahuja, Yu-Chong Tai, David R. Hinton, Robert H. Grubbs, Dennis O. Clegg, Lincoln Vallance Johnson, Sherry T. Hikita